Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting

Executive Summary

Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.

Advertisement

Related Content

Spark's Gene Therapy Luxturna Sails Through US FDA Panel
Spark's Vision Loss Gene Therapy Raises US FDA Questions About Novel Endpoint
Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy
ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval
Gene Therapy Reimbursement: Is Blindness A Bad First Test?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel